Biotech Startups

Net-Targets applies AI-enhanced systems biology to identify drug targets and mechanisms for pharmaceutical development. The company combines biological experimentation, mathematical modeling, and computer simulation to uncover hidden biological networks that inform medicine development.

1 investor

NE Tech uses patented extraction technology developed at the University of Canterbury to produce high-purity active ingredients for the dietary supplement industry. Its room-temperature process aims to lower cost and waste while improving taste of the extracts.

1 investor

Neucore Bio develops precision therapeutics using engineered exosomes derived from fibroblasts to deliver molecular-level cellular repair and renewal across genetic and degenerative diseases with high unmet medical needs.

1 investor

NeuExcell Therapeutics is a clinical-stage gene therapy company developing treatments for neurodegenerative and neurological diseases such as glioma, Alzheimer's disease, and stroke. Its ATN (Astrocytes To Neurons) platform converts glial cells into functional neurons in vivo to repair damaged brain tissue.

1 investor

Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases. It focuses on innovation in both product and process development to lower cell therapy production costs and expand indication coverage.

1 investor

Neumarker develops machine learning and biophysical tools to advance neuropsychiatric drug development and clinical care for CNS disorders. The company serves pharmaceutical and clinical organizations working on psychiatric and neurological treatments.

1 investor

Neumentum is a specialty pharmaceutical company developing non-opioid analgesic and neurology products for pain management. It has four novel non-opioid products in development aimed at treating pain while avoiding the abuse, misuse, and respiratory side effects associated with opioids.

1 investor

NeuralTeks develops AI-powered tools for laboratory analysis, specifically targeting microbiology and microbial identification in pharmaceutical, biotechnology, and analytical settings. The platform aims to accelerate analysis speed, improve accuracy, and reduce costs for laboratory operations.

1 investor

Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative disorders, focusing on inhibiting pathological glial activation to prevent neuronal cell death. Its lead candidate NLY01 has been evaluated in Phase 2 trials for early Parkinson's disease.

1 investor

Developing a novel treatment for acute muscle spasms.

1 investor

Neurescue develops a medical device that treats cardiac arrest patients by inserting a balloon-occlusion device through the femoral artery to increase blood flow to the heart and brain during chest compressions. The device targets patients ineligible for defibrillation and uses automated pressure-limited inflation to improve resuscitation outcomes.

1 investor

Neurobiome LLC is developing the M.E. Gut-Brain chip, a microfluidic screening tool that uses dynamic flow and high-throughput testing to identify microbiome-mediated neuroactive compounds and probiotic strains. It targets early-stage screening for probiotic and pharmaceutical development aimed at mental and neurological health conditions.

1 investor

Neuro-Bio is an Oxfordshire-based biotech company developing a biomarker and a diagnostic for Alzheimer's disease based on a novel hypothesis of the neurodegenerative process, originating from research at Oxford University. It also pursues neuroprotection approaches, with its first patent covering chemical composition of matter.

1 investor

Neurochase provides consultancy to biotech and pharmaceutical companies on directly delivering therapies to the central nervous system, drawing on experience with catheter infusions and convection-enhanced delivery. It supports preclinical study protocols, toxicology, surgical workflow and training, and is developing its own CED drug-delivery devices.

1 investor

NeuroDex develops blood-based biomarkers and diagnostic assays for neurological diseases, including rare genetic disorders, Parkinson's disease, Alzheimer's disease, and ALS. The company works with biopharmaceutical companies to enable patient selection, treatment monitoring, and accelerated disease diagnosis in clinical development programs.

1 investor

Neurodon develops small-molecule therapeutics that target cellular calcium imbalance and the endoplasmic reticulum stress pathway, using compounds that allosterically modulate the SERCA enzyme to restore calcium transport. Its disease-modifying approach aims at conditions linked to cellular stress such as diabetes, Alzheimer's, Parkinson's, and Duchenne muscular dystrophy.

1 investor

Neurodyn Life Sciences is a biotech incubator that identifies and develops natural bioactives into prescription drugs and natural products for neurological diseases and brain health. It runs preclinical drug programs (including progranulin/granulin therapies for ALS) through its in-house CRO and spins mature projects into standalone or partnered businesses.

1 investor

NeuroGevity develops a sleep headband with biometric sensors and AI algorithms to assess brain health and detect neurophysiological biomarkers at home. The company also offers sound-based stimulation synchronized to brain activity to enhance slow-wave sleep and memory consolidation.

1 investor

NeuroGenesis develops cell therapies for neurodegenerative diseases, leveraging its NG CELL platform to enhance stem cells for treating conditions like multiple sclerosis and ALS. The company is advancing Phase IIb clinical trials in Europe and Israel with a focus on remyelinating and regenerative cellular medicine.

1 investor

Neurolentech develops therapeutics for neurodevelopmental disorders such as epilepsy, intellectual disability, and severe autism, using patient-derived neuronal cell models to identify druggable targets and accelerate drug discovery. It works with clinicians and patient foundations, including the Tess Foundation, to develop treatments for indications like SLC13A5 epilepsy.

1 investor

Neurolieve is a life-science company developing therapeutics for neuropathic and chronic pain, with expertise in neuroscience, clinical pain medicine and drug development. Its lead program, NLV-01, is built on protein-engineering technology contributed by co-founding partner LifeArc.

1 investor

Neuronity develops therapies that enhance immune cell activity in the aging brain to prevent neurodegenerative disease progression. The company targets patients with age-related neurological conditions.

1 investor

NeurOp develops novel pharmaceutical compounds targeting NMDA receptors for the treatment of pain, stroke, subarachnoid hemorrhage, and severe depression. The company's lead candidate, NP10679, is in early-stage clinical development.

1 investor

Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.

1 investor